L&C BIO Co.,LTD (KOSDAQ: 290650)

L&C BIO Co.,LTD Statistics

Total Valuation

L&C BIO Co.,LTD has a market cap or net worth of KRW 432.37 billion. The enterprise value is 484.40 billion.

Market Cap	432.37B
Enterprise Value	484.40B

Important Dates

The next estimated earnings date is Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

L&C BIO Co.,LTD has 22.68 million shares outstanding. The number of shares has increased by 8.98% in one year.

Shares Outstanding	22.68M
Shares Change (YoY)	+8.98%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	29.86%
Owned by Institutions (%)	15.06%
Float	15.32M

Valuation Ratios

The trailing PE ratio is 8.98.

PE Ratio	8.98
Forward PE	n/a
PS Ratio	6.00
PB Ratio	2.91
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.42, with an EV/FCF ratio of -12.40.

EV / Earnings	9.88
EV / Sales	6.72
EV / EBITDA	37.42
EV / EBIT	69.16
EV / FCF	-12.40

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.51.

Current Ratio	1.23
Quick Ratio	0.64
Debt / Equity	0.51
Debt / EBITDA	6.33
Debt / FCF	-2.10
Interest Coverage	1.13

Financial Efficiency

Return on equity (ROE) is 36.88% and return on invested capital (ROIC) is 2.00%.

Return on Equity (ROE)	36.88%
Return on Assets (ROA)	1.87%
Return on Capital (ROIC)	2.00%
Revenue Per Employee	581.00M
Profits Per Employee	395.22M
Employee Count	124
Asset Turnover	0.31
Inventory Turnover	0.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.34% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-38.34%
50-Day Moving Average	18,792.80
200-Day Moving Average	22,236.90
Relative Strength Index (RSI)	55.07
Average Volume (20 Days)	88,805

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 72.04 billion and earned 49.01 billion in profits. Earnings per share was 2,122.03.

Revenue	72.04B
Gross Profit	36.66B
Operating Income	7.00B
Pretax Income	64.40B
Net Income	49.01B
EBITDA	12.94B
EBIT	7.00B
Earnings Per Share (EPS)	2,122.03

Balance Sheet

The company has 40.62 billion in cash and 81.91 billion in debt, giving a net cash position of -41.28 billion or -1,819.79 per share.

Cash & Cash Equivalents	40.62B
Total Debt	81.91B
Net Cash	-41.28B
Net Cash Per Share	-1,819.79
Equity (Book Value)	159.19B
Book Value Per Share	6,543.93
Working Capital	21.58B

Cash Flow

In the last 12 months, operating cash flow was -15.00 billion and capital expenditures -24.05 billion, giving a free cash flow of -39.05 billion.

Operating Cash Flow	-15.00B
Capital Expenditures	-24.05B
Free Cash Flow	-39.05B
FCF Per Share	-1,721.57

Margins

Gross margin is 50.89%, with operating and profit margins of 9.72% and 68.03%.

Gross Margin	50.89%
Operating Margin	9.72%
Pretax Margin	89.39%
Profit Margin	68.03%
EBITDA Margin	17.97%
EBIT Margin	9.72%
FCF Margin	-54.21%

Dividends & Yields

This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.51%.

Dividend Per Share	100.00
Dividend Yield	0.51%
Dividend Growth (YoY)	100.00%
Years of Dividend Growth	1
Payout Ratio	4.63%
Buyback Yield	-8.98%
Shareholder Yield	-8.47%
Earnings Yield	11.13%
FCF Yield	-9.03%

Stock Splits

The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.

Last Split Date	Oct 12, 2020
Split Type	Forward
Split Ratio	3

Scores

L&C BIO Co.,LTD has an Altman Z-Score of 4.86.

Altman Z-Score	4.86
Piotroski F-Score	n/a